CMS expands TAVR Medicare coverage to asymptomatic patients
Published . Updated .
The Centers for Medicare and Medicaid Services’ policy update extends Medicare coverage to severe aortic stenosis patients without symptoms, a change that analysts said will especially benefit Edwards Lifesciences.
Directly affected
- EW Edwards Lifesciences
Named in this report.
Indirectly affected
- SPY SPDR S&P 500
The broad U.S. stock market
- TLT iShares 20+ Year Treasury Bond
Long-term U.S. government bonds
- QQQ Invesco QQQ
Large technology stocks
- GLD SPDR Gold Shares
Gold can move with the broad market
Price reaction, T-5 to T+3
The Centers for Medicare and Medicaid Services’ policy update extends Medicare coverage to severe aortic stenosis patients without symptoms, a change that analysts said will especially benefit Edwards Lifesciences.
Source: MedTech Dive
Price since this story was published: Edwards Lifesciences (EW)
Since the first closing price after “CMS expands TAVR Medicare coverage to asymptomatic patients,” Edwards Lifesciences (EW) is +1.98%. The S&P 500 fund (SPY) is +0.77% over the same days, a +1.21% difference versus the market.
Disclosure records for Edwards Lifesciences (EW) within two months of 12 Sep 2026
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who is named in “CMS expands TAVR Medicare coverage to asymptomatic patients”
Companies mentioned with this story
- EW Edwards Lifesciences
Edwards Lifesciences (EW) is linked, with no stored direction, high confidence in the 12 Sep 2026 story “CMS expands TAVR Medicare coverage to asymptomatic patients.” Reason on file: The reported development directly names EDWARDS LIFESCIENCES CORP in the summary; GA resolved that company to EW
How “CMS expands TAVR Medicare coverage to asymptomatic patients” reaches Edwards Lifesciences (EW)
The 12 Sep 2026 story “CMS expands TAVR Medicare coverage to asymptomatic patients” names Edwards Lifesciences (EW) because of this story.
Edwards Lifesciences (EW) is on the page because The reported development directly names EDWARDS LIFESCIENCES CORP in the summary; GA resolved that company to EW
Dates and price levels for Edwards Lifesciences (EW)
EW traded between 82.44 and 89.65 across 20 sessions. The latest close on file is 87.21.
How strong the case is around Edwards Lifesciences (EW)
14 out of 100
“CMS expands TAVR Medicare coverage to asymptomatic patients” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.